2021 U.S. Generic and Biosimilar Medicines Savings Report

The report proves that the promise of biosimilars is coming to fruition. As patient access to lower-cost biosimilars grew in 2020, savings skyrocketed.

Learn More

Biosimilars are a prescription for better health.

Biosimilars could lead to over $130 billion in savings by 2025, giving 1.2 million patients access to needed medicines.

Learn More

Access! 2022

Access! brings together policymakers, influential speakers and industry leaders to chart the future of generics and biosimilars. Plan to join us in person for the first time since 2019 in Orlando, FL!  Sign up before December 31, 2021 to receive $500 off full-pass registration.
secure our meds white paper

Roadmaps for Ensuring Patient Access to Generic and Biosimilar Medicines

This paper examines the challenges to market sustainability for generic and biosimilar medicines that have cleared the regulatory and patent hurdles to obtain FDA approval and launch into the U.S. market.


Browse our Resources

Hear more from experts on the potential of biosimilars and learn about Biosimilars Council efforts to increase biosimilar access for patients.


Want to keep up-to-date?

Enter your email address below and receive the Biosimilars Bulletin – our monthly newsletter with the most recent information on biosimilars in the United States.

  • This field is for validation purposes and should be left unchanged.

FDA Biosimilars Approvals

Find an up-to-date list of FDA approved biosimilars and launches.

Featured Reports & Resources

These resources provide answers around what biosimilars are, why they are important, how they can improve patient access, and how they can save the United States billions of dollars.

Biosimilars Council, Biosimilars Council
Biosimilars Council, Biosimilars Council
Biosimilars Council, Biosimilars Council
failure to launch white paper

Recent Tweets